Wire · opportunities
Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
Cardurion Pharmaceuticals presented positive Phase 2 trial results for tovinontrine, a novel PDE9 inhibitor that significantly reduced the heart failure biomarker NT-proBNP in patients with heart failure with reduced ejection fraction (HFrEF) alongside existing treatments, showing a favorable safety profile.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can position your biotech company to explore PDE9 as a regulatory target in heart failure, following Cardurion's proof that tovinontrine works with standard therapies. Fast-track collaborations or product pivot around PDE9 inhibition could open an underserved treatment niche.
◆ Coverage
1 source · 11 Oct 2026
◆ Related on Wire
◆ Topics